Hims & Hers Health (NYSE:HIMS) run trims Canaccord upside after GLP-1 reset

Hims & Hers Health jumped 9.5% to $37.97 by midday after Canaccord Genuity’s Maria Ripps raised her target price to $40 from $32 and left her Buy call unchanged. The new target is about 5% above the current level, after a 25% bump in the target price.

NYSE:HIMS · Pharmaceutical News · Stock Market
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Inc shares gained in early U.S. premarket trading Monday after late-stage trial results reported its experimental pill for pancreatic cancer almost doubled survival against chemo. RVMD was last seen at $157.48, up $2.93, or 1.9%, ahead of the regular Nasdaq open. The company’s market cap hovered at about $31.2 billion. Nasdaq’s 2026 calendar does not list June 1 as a holiday—Memorial Day shows May 25 and Juneteenth June 19 as closures.
1 June 2026
···
Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Why Ernexa Therapeutics Stock Jumped After ERNA-101 Ovarian Cancer Survival Data

Ernexa Therapeutics Inc. reported Wednesday that its lead cell therapy, ERNA-101, paired with PD-1 blockade, wiped out tumors completely and delivered 100% long-term survival in preclinical ovarian cancer studies. “Complete tumor eradication and durable survival,” is how Chief Scientific Officer Robert H. Pierce summed up the results. Chief Executive Sanjeev Luther called the data “beyond expectations.”
6 May 2026
···
Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Stock Jumps 16% as Gedatolisib Breast-Cancer Data Raise FDA Stakes

Celcuity Inc. shares surged close to 16% Monday, after the Minneapolis-based biotech announced late Friday its lead drug candidate, gedatolisib, hit the primary endpoint in a late-stage breast cancer trial for patients with PIK3CA-mutant tumors. That news brought back attention to a July FDA decision and a planned cancer conference update in June for CELC stock.
4 May 2026
···
Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics Stock Jumps After Hours Ahead of First Phase 3 In Vivo CRISPR Readout

Intellia Therapeutics is slated to release top-line results Monday from HAELO, its pivotal trial of lonvoguran ziclumeran—an experimental, one-and-done therapy aimed at hereditary angioedema. The company bills this as the first-ever Phase 3 data for an in vivo CRISPR gene-editing therapy, meaning the genetic tweak happens directly in the patient rather than in lab-modified cells.
25 April 2026
···
ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio stock jumps 35% as ANKTIVA bladder cancer trial update puts FDA filing in view

ImmunityBio shares jumped about 35% on Friday after the cancer drugmaker reported faster enrollment and stronger interim results in a key bladder cancer study for its ANKTIVA therapy. The stock was up $1.39 at $5.34 by 12:51 p.m. EST after hitting $5.53, with about 133 million shares traded. The company said more than 85% of patients are enrolled in its QUILT-2.005 trial and it is targeting a U.S. filing by the end of 2026; an interim analysis showed 85% of patients on ANKTIVA plus BCG stayed in complete response at six months versus 57% on BCG alone and 84% versus 52% at nine months.
16 January 2026
···
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines Inc shares rose 13.25% on Monday to close at $304.58, after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for its essential tremor candidate ulixacaltamide, a filing showed. The stock opened at $317.72 and traded between $298 and $317.72, and was down about 1% in after-hours trading. StockAnalysis+2SEC+2
30 December 2025
···
1 2 3
Follow on Google News
Add as preferred source Open in Google News

US Stock Market Today Updates

MARKET CALENDAR

Key Events Today

The catalysts most likely to move markets.

#1

Warsh at Jackson Hole

Policy tone can move rates, USD, equities, gold and crypto simultaneously.

#2

Michigan sentiment

A weak final reading or elevated inflation expectations could pressure risk assets.

#3

Chicago PMI

A surprise versus 58.0 may alter the near-term manufacturing-growth narrative.

View full calendar
Times and estimates may change. Verify before trading.